HUTCHMED (NASDAQ:HCM) Upgraded at Daiwa Securities Group

Daiwa Securities Group upgraded shares of HUTCHMED (NASDAQ:HCM) from a hold rating to a buy rating in a report published on Thursday morning, Marketbeat reports.

HCM has been the topic of a number of other reports. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Bank of America cut their target price on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Weiss Ratings lowered HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, July 31st. The Goldman Sachs Group decreased their price target on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, July 23rd. Finally, Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $14.87.

HUTCHMED Stock Down 0.1%

Shares of HCM stock opened at $14.09 on Thursday. The firm’s 50 day moving average is $11.76 and its 200 day moving average is $12.73. HUTCHMED has a 12 month low of $9.77 and a 12 month high of $18.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64.

HUTCHMED (NASDAQ:HCM) last issued its earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The business had revenue of $139.14 million for the quarter, compared to analyst estimates of $304.16 million. As a group, research analysts expect that HUTCHMED will post 0.33 earnings per share for the current fiscal year.

Institutional Trading of HUTCHMED

Institutional investors and hedge funds have recently modified their holdings of the business. XY Capital Ltd increased its position in shares of HUTCHMED by 115.2% in the second quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock worth $1,120,000 after purchasing an additional 55,736 shares during the last quarter. Amundi lifted its position in HUTCHMED by 4.0% during the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after purchasing an additional 8,916 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in HUTCHMED in the 1st quarter worth approximately $365,000. State Street Corp increased its holdings in shares of HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after buying an additional 3,801 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of HUTCHMED by 3.0% in the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $1,798,000 after buying an additional 3,900 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED News Roundup

Here are the key news stories impacting HUTCHMED this week:

• Positive Sentiment: HUTCHMED granted GSK exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumors. The deal includes a $110 million upfront payment and could generate up to $1.295 billion in total milestone payments, plus royalties. Reuters article
• Positive Sentiment: The partnership validates HUTCHMED’s oncology pipeline through a major global pharmaceutical partner and could provide funding and development support for HMPL-A830. The drug is expected to enter clinical trials in the second half of 2026. HUTCHMED announcement
• Positive Sentiment: Daiwa Securities upgraded HCM from “hold” to “buy.” Panmure and Cavendish also reiterated “buy” ratings, citing the GSK deal and what they view as an overlooked valuation relative to HUTCHMED’s expanding oncology pipeline. Broker responses
• Neutral Sentiment: Management discussed the strategic partnership and licensing arrangement in an investor transcript, providing additional details on HMPL-A830’s development and the collaboration with GSK. Seeking Alpha transcript
• Negative Sentiment: HMPL-A830 remains an experimental therapy, so the milestone value is contingent on successful clinical development, regulatory approvals and commercialization. Investors may therefore continue to weigh substantial drug-development risk despite the sizable headline deal.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.